10-K: AppYea Inc. Reports Full Year 2023 Results, Focuses on Wearable Sleep Tech

AppYea Inc., a digital health company, released its 2023 annual report, highlighting its focus on developing wearable solutions for sleep apnea and snoring, while navigating financial challenges.

Summary

• AppYea Inc. is a digital health company focused on developing wearable monitoring solutions for sleep apnea and snoring.
• The company's solutions are based on proprietary AI and sensing technologies for tracking and diagnosing vital signs during sleep.
• The company is developing two main devices: AppySleep, a biofeedback snoring treatment wristband, and AppySleep LAB, a medical app for monitoring breathing patterns to identify sleep apnea.
• AppySleep PRO, a wristband for sleep apnea treatment, is also in development.
• The company started marketing the AppySleep app and wristband in the first quarter of 2024.
• AppYea plans to file a 510(k) FDA submission for AppySleep LAB in 2024 and for AppySleep PRO in 2026.
• The company's net losses for 2023 and 2022 were $1.817 million and $1.304 million, respectively, with an accumulated deficit of $6.326 million as of December 31, 2023.
• The company anticipates needing an additional $5 million to complete product development and build infrastructure.
• The company has a licensing agreement with B.G. Negev Technologies and Applications Ltd. and Mor Research Application Ltd. for its core technology, which includes royalty payments and milestone payments.
• The company has a monthly manufacturing capacity of 48,000 units for its bracelets in China.
• The company is subject to extensive regulation by the FDA and other regulatory bodies.

Sentiment

Score: 4

Explanation: The document highlights the company's innovative technology and market potential, but the significant financial losses, need for additional capital, and going concern warning create a negative sentiment. The company is in a high-risk, high-reward situation.

Positives

• The company has a proprietary technology platform based on AI and sensing technologies.
• The company has a licensing agreement for its core technology.
• The company has a manufacturing capacity in place for its initial product.
• The company has a clear strategy for product development and commercialization.
• The company has started marketing its AppySleep product in the first quarter of 2024.

Negatives

• The company has incurred significant losses and has an accumulated deficit.
• The company needs substantial additional capital to fund its operations.
• The company is subject to extensive regulatory requirements and may face delays in obtaining approvals.
• The company is dependent on third-party manufacturers and suppliers.
• The company faces competition in the health tech market.

Risks

• The company has a limited operating history and is subject to risks inherent in new business enterprises.
• The company may not be able to obtain the necessary capital to fund its operations.
• The company's products may not be successfully commercialized.
• The company's licensing agreement could be terminated under certain conditions.
• The company may face difficulties in managing its growth and operations.
• The company's IT systems are vulnerable to cyberattacks and security breaches.
• The company may face difficulties in obtaining third-party reimbursement for its products.
• The company's clinical trials could be delayed or unsuccessful.
• The company's patents may not be upheld or may infringe on others' patents.
• The company's products may become technologically obsolete.
• The company may be subject to litigation.
• The company's operations in Israel are subject to political and military instability.
• The company's stock price could decline, affecting its ability to raise capital.
• The company's stock is subject to penny stock rules, making trading difficult.
• The company has not paid dividends and does not intend to in the foreseeable future.
• The company's chairman has significant influence over its affairs.
• The company has a going concern warning.

Future Outlook

The company plans to file for FDA approval for AppySleep LAB in 2024 and AppySleep PRO in 2026 and aims to establish its technology as the gold standard in its targeted sectors within the next five years. The company also plans to continue developing big data-based algorithms for predicting life-threatening illnesses and health events.

Management Comments

• Management believes that funds on hand will enable the company to fund operations and capital expenditure requirements through the end of the third quarter of 2024.
• Management believes that the company will need to raise additional operating capital in order to maintain operations as presently conducted and to realize its business plan.

Industry Context

The global anti-snoring treatment market is expected to grow to USD 8.6 billion by 2028, and the global sleep apnea device market is expected to reach USD 6.1 billion by 2028, indicating a significant market opportunity for AppYea's products. The company is competing with existing solutions such as oral appliances and CPAP machines.

Comparison to Industry Standards

• The company's focus on wearable technology and AI-based solutions aligns with the trend of at-home diagnostics and treatment in the sleep disorder market.
• ResMed is a major competitor in the sleep apnea device market, particularly in the CPAP segment.
• The company's approach of using biofeedback to treat sleep apnea differs from traditional CPAP therapy.
• The company's AppySleep LAB app aims to provide a more convenient and cost-effective alternative to traditional sleep lab testing.
• The company's reliance on third-party manufacturers is common in the medical device industry, but it also introduces supply chain risks.

Management Changes

Legal Proceedings

• A lawsuit was filed against the company's chairman and other related parties in Israel, alleging breach of partnership and loan agreements.
• The lawsuit has been transferred to the economic department of the District Court in Tel Aviv, and the parties are attempting mediation.

Related Party Transactions

• The company has a licensing agreement with Nexense Technologies USA Inc., a related party.
• The company has a consulting agreement with GPIS Ltd, an Israeli company where the sole shareholder is the company's Chief Executive Officer.
• The company has outstanding loans from related parties, including Boris Molchadsky and Nexense Technologies USA Inc.

Stakeholder Impact

• Shareholders face the risk of dilution and potential loss of investment due to the company's need for additional capital.
• Employees may be affected by potential cost reduction measures or delays in development programs.
• Customers may benefit from the company's innovative products, but they also face the risk of product delays or failures.
• Suppliers and creditors face the risk of non-payment due to the company's financial challenges.

Next Steps

• The company plans to file a 510(k) FDA submission for the AppySleep LAB app in 2024.
• The company plans to file for FDA approval for AppySleep PRO in 2026.
• The company plans to continue developing big data-based algorithms for predicting life-threatening illnesses and health events.
• The company plans to continue marketing its AppySleep product.

Key Dates

Keywords

sleep apnea, snoring, wearable technology, digital health, biofeedback, FDA approval, AI, licensing agreement, medical devices, health tech